
Sign up to save your podcasts
Or
Aspirin for primary prevention, time-restricted feeding, renal denervation, and a potential new obesity drug are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – ASA for Primary Prevention:
- USPSTF Final Recommendation on Aspirin for Primary CV Prevention https://www.medscape.com/viewarticle/972761
- Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2791399
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly https://www.nejm.org/doi/10.1056/NEJMoa1805819
- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1803955
II – Time Restricted Feeding
- Is There a Benefit to Fasting Plus Calorie Counting? https://www.medscape.com/viewarticle/972579
- Calorie Restriction with or without Time-Restricted Eating in Weight Loss https://www.nejm.org/doi/full/10.1056/NEJMoa2114833
- Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. The TREAT Randomized Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095
III – Renal Denervation
- Renal Denervation BP Benefits Remain at 3 Years: SPYRAL HTN-ON https://www.medscape.com/viewarticle/971883
- Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial https://doi.org/10.1016/S0140-6736(22)00455-X
IV – Tirzepatide for Obesity
- Tirzepatide Excites in Obesity Now Too, Says Lilly https://www.medscape.com/viewarticle/972936
- Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 https://www.prnewswire.com/news-releases/lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-surmount-1--301534871.html
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
4.9
833833 ratings
Aspirin for primary prevention, time-restricted feeding, renal denervation, and a potential new obesity drug are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – ASA for Primary Prevention:
- USPSTF Final Recommendation on Aspirin for Primary CV Prevention https://www.medscape.com/viewarticle/972761
- Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2791399
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly https://www.nejm.org/doi/10.1056/NEJMoa1805819
- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1803955
II – Time Restricted Feeding
- Is There a Benefit to Fasting Plus Calorie Counting? https://www.medscape.com/viewarticle/972579
- Calorie Restriction with or without Time-Restricted Eating in Weight Loss https://www.nejm.org/doi/full/10.1056/NEJMoa2114833
- Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. The TREAT Randomized Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095
III – Renal Denervation
- Renal Denervation BP Benefits Remain at 3 Years: SPYRAL HTN-ON https://www.medscape.com/viewarticle/971883
- Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial https://doi.org/10.1016/S0140-6736(22)00455-X
IV – Tirzepatide for Obesity
- Tirzepatide Excites in Obesity Now Too, Says Lilly https://www.medscape.com/viewarticle/972936
- Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 https://www.prnewswire.com/news-releases/lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-surmount-1--301534871.html
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
133 Listeners
13 Listeners
314 Listeners
166 Listeners
492 Listeners
18 Listeners
3,325 Listeners
90 Listeners
137 Listeners
1,116 Listeners
58 Listeners
191 Listeners
513 Listeners
349 Listeners
60 Listeners
25 Listeners
8 Listeners
248 Listeners
425 Listeners
365 Listeners